Tag Archives: Circulating Tumor DNA

Over the last decades, the concept of precision medicine has dramatically renewed the field of medical oncology; the introduction of patient-tailored therapies has significantly improved all measurable outcomes. Liquid biopsy is a revolutionary technique...

Adding a blood test called liquid biopsy to a standard tissue biopsy could significantly improve the accuracy of diagnosis and treatment for patients with cancer, according to researchers at Wake Forest Baptist Medical Center. Their recommendation is...

The detection of cancer biomarkers represents an important aspect of cancer diagnosis and prognosis. Recently, the concept of liquid biopsy has been introduced whereby diagnosis and prognosis are...

The therapeutic landscape of lung cancer has expanded significantly over the past decade. Advancements in molecularly targeted therapies, strategies to discover and treat resistance mutations, and development of personalized cancer treatments in the context of tumor heterogeneity and dynamic tumor ...

 Natera, Inc, a leader in non-invasive genetic testing, today announced the launch of SignateraTM, a circulating tumor DNA (ctDNA) technology that analyzes and tracks mutations specific to an individual’s tumor, for research use only (RUO) by oncology researchers and biopharmaceutical ...

There is a growing trend towards exploring the use of a minimally invasive “liquid biopsy” to identify biomarkers in a number of cancers, including urologic malignancies. Multiple aspects can be assessed in circulating cell-free DNA, including cell-free DNA levels, integrity, ...

Characterizing and monitoring tumor genomes with blood samples could achieve significant improvements in precision medicine. As tumors shed parts of themselves into the circulation, analyses of circulating tumor cells, circulating tumor DNA, and tumor-derived exosomes, often referred to as “liquid ...

Agena Bioscience today introduced new targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSEEK™ Lung and Colon Panels enable detection of mutations as low as 0.1% minor allele frequency (MAF) from circulating tumor ...

Exosomes arise from viable cancer cells and may reflect a different biology than circulating cell-free DNA (cfDNA) shed from dying tissues. Researchers from the University of Texas MD Anderson Cancer Center compared exosome-derived DNA (exoDNA) to cfDNA in liquid biopsies ...

San Francisco, CA | Translational Medicine Job Summary This position will be responsible for biomarker discovery and diagnostic development for rucaparib and other Clovis programs. This positon will work effectively with Translational Medicine, Biostatistics, Clinical Development, Regulatory, Clinical Operation, and ...